Evaluation of the Efficacy of Ginger Supplementation with Pellet Formulation in Children with Juvenile Idiopathic Arthritis(JIA)
Not Applicable
Recruiting
- Conditions
- juvenile idiopathic arthritis (JIA).Juvenile arthritis
- Registration Number
- IRCT20191221045837N4
- Lead Sponsor
- Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Children (aged 6-16 years) referred to rheumatology clinic of Akbar hospital, who have been diagnosed with JIA according to the ACR Guideline.
Obtaining informed consent of the patient / patient's parents
Exclusion Criteria
A child with a history of underlying disease, including cardiac, renal, hepatic, biliary, gastrointestinal, or rheumatic disorders (other than JIA), at the time of enrollment
Use of anticoagulants (such as warfarin) or antiplatelet agents
Diabetic patients
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Disease severity will be assessed at baseline, end of the first month, and end of the third month of treatment using the ACR-Pedi30 Score. The core criteria for ACR Pedi 30 score are: 1) physician global assessment of disease activity (PhGA); 2) parent/patient global assessment of overall well-being; 3) functional ability; 4) number of joints with active arthritis; 5) number of joints with limited range of motion; and 6) ESR. Timepoint: At baseline, end of the first month, and end of the third month of treatment. Method of measurement: 1) physician global assessment of disease activity (PhGA); 2) parent/patient global assessment of overall well-being; 3) functional ability; 4) number of joints with active arthritis; 5) number of joints with limited range of motion; and 6) ESR.
- Secondary Outcome Measures
Name Time Method